Takeda Liable for 885 Million Dollars in Antitrust Case
A federal jury in Boston found Takeda Pharmaceutical liable for delaying a generic version of the constipation drug Amitiza through an anticompetitive scheme. The initial award of 885 million dollars could triple to over 2.4 billion dollars under federal antitrust laws as the company plans an appeal.
Xurve View
Insights:
Xurve View
Takeda Pharmaceutical Co Ltd must pay $885 million after a United States jury found it delayed a generic constipation drug. It is the first jury-awarded liability for "pay-for-delay" schemes since a 2013 Supreme Court ruling. The verdict threatens Takeda's earnings as statutory tripling could push the total penalty to $2.47 billion.
